- See Also
-
Links
- “Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
- “Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial”, Wadden et al 2023
- “A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
- “Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): a Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial”, Garvey et al 2023
- “Lilly's Tirzepatide Achieved up to 15.7% Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2”, Lilly 2023
- “Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): a Double-Blind, Multicentre, Randomized, Phase 3 Trial”, Inagaki et al 2022
- “Tirzepatide Once Weekly for the Treatment of Obesity”, Jastreboff et al 2022
- “FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Lilly 2022
- “Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, Lilly & Company 2022
- “Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Dahl et al 2022
- “Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
- “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, Prato et al 2021
- “Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec As Add-On to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomized, Open-Label, Parallel-Group, Phase 3 Trial”, Ludvik et al 2021
- “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Frías et al 2021
- “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-Blind, Randomized, Phase 3 Trial”, Rosenstock et al 2021
- “Society Is Fixed, Biology Is Mutable”
- Wikipedia
- Miscellaneous
- Link Bibliography
See Also
Links
“Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
“Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial”, Wadden et al 2023
“A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023
“Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): a Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial”, Garvey et al 2023
“Lilly's Tirzepatide Achieved up to 15.7% Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2”, Lilly 2023
“Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): a Double-Blind, Multicentre, Randomized, Phase 3 Trial”, Inagaki et al 2022
“Tirzepatide Once Weekly for the Treatment of Obesity”, Jastreboff et al 2022
“FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Lilly 2022
“Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, Lilly & Company 2022
“Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Dahl et al 2022
“Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
“Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, Prato et al 2021
“Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec As Add-On to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomized, Open-Label, Parallel-Group, Phase 3 Trial”, Ludvik et al 2021
“Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Frías et al 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]
“Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-Blind, Randomized, Phase 3 Trial”, Rosenstock et al 2021
“Society Is Fixed, Biology Is Mutable”
Wikipedia
Miscellaneous
Link Bibliography
-
2023-lingvay.pdf: “A Revolution in Obesity Treatment”, Ildiko Lingvay, Shubham Agarwal -
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and: “FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Eli Lilly -
2021-delprato.pdf: “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomized, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial”, -
2021-frias.pdf: “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”,